Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In Capan-1 mouse xenograft model, AZD1775 plus AZD0156 (ATM inhibitor) treatment reduced tumor growth and downregulated tumor expression of PD-L1, CMTM6, CD163, and CXCR2, all of which contribute to tumor immune evasion.
|
31291716 |
2020 |
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We found enrichment of ATM mutations in ICPI-refractory tumors (P=0.01) to correlate with worse survival (4.2 vs. 10 mo, P=0.03).
|
31567705 |
2020 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Therapeutic Potential of the microRNA-ATM Axis in the Management of Tumor Radioresistance.
|
31767626 |
2020 |
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
However, absence of the familial microdeletion in at least one affected family member suggests that ATM deletions are unlikely the sole contributing factor influencing tumor development in affected individuals.
|
31671381 |
2020 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A proximity ligation assay further confirmed an association between ATM and EZH2 in tumors of patients with an increased disease-free survival.
|
31704732 |
2020 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
ATM is a well-established tumour suppressor.
|
31565865 |
2019 |
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Regarding qualitative imaging features, on univariate analysis, tumor location was significantly associated with APC (p = 0.032) and RASA1 mutation (p = 0.032); CRM status was significantly associated with ATM mutation (p = 0.021); and lymph node metastasis was significantly associated with BRCA2 (p = 0.046) mutation.
|
30927944 |
2019 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
These results provide new insight into PDA initiation and reveal ATDC as a potential target for preventing early tumor-initiating events.
|
31048544 |
2019 |
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The prognostic impact of ATM mutations was independent from TP53 mutational status and primary tumor location.
|
30814645 |
2019 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Tumor immunogenicity was evaluated after ATM inhibition alone and in combination with radiation by assessing TBK1 and Type I interferon (T1IFN) signaling as well as tumor growth following PD-L1/PD-1 checkpoint inhibition.
|
31101760 |
2019 |
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In addition, we analyzed seven prostate cancer biopsies that were either BRCA2 or ATM-mutated in comparison with wild-type tumors.
|
31549213 |
2019 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A phase II study (Study 39; NCT01063517) designed to investigate the combination olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer did not meet its primary endpoint of progression-free survival; however, an improvement in the secondary endpoint of overall survival was recorded with a greater overall survival benefit noted in patients with ATM-negative tumors.
|
31206368 |
2019 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Although the angiotensin II (AngII)/AT1 receptor system is best known for mediating blood pressure and body water/electrolyte balance it also facilitates tumor vascularization and growth by stimulating the expression of VEGF.
|
30914029 |
2019 |
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In MYC over expressed tumours, high ATR or low ATM levels were associated with aggressive breast cancer features such as higher tumour grade, de-differentiation, pleomorphism, high mitotic index, high-risk Nottingham Prognostic Index, triple negative and basal-like breast cancers (all adjusted p values < 0.05).
|
30746633 |
2019 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Oncogene-induced replication stress serves as a tumour specific vulnerability and rationale for the clinical development of inhibitors targeting the DNA damage response (DDR) kinases (CHK1, ATR, ATM and WEE1).
|
31500184 |
2019 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Cells and tissues lacking ATM are prone to tumor development and enhanced tumor cell migration and invasion.
|
30553448 |
2019 |
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Abnormal DNA damage response protein expression, defined as loss of any one of NBS1, BRCA1, ATM, and/or abnormal p53 expression, was observed in 258 of 399 evaluable cases (64.7%) and was significantly associated with higher tumor grade, larger tumor size, and ER-negative, and/or PR-negative status.
|
30671767 |
2019 |
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
ATM is a kinase activated by autophosphorylation upon DNA doublestrand breaks arising from errors during replication, byproducts of metabolism, chemotherapy or ionizing radiations; TP53 is one of the most popular tumor suppressor, with a preeminent role in DNA damage response and repair.
|
29369420 |
2018 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Genomic alterations significantly co-occurred in the tumor suppressor gene ATM with the following genes: SMARCB1, EGFR exon 7, RET and KDR.
|
30093964 |
2018 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Network interactions of proteins involved in tumor growth (Ki67, ATM) and/or affect the oxidation state of the cell (HIF-1a, iNOS, aGluc) were revealed, that may contribute to the risk of developing acute radiation dermatitis.
|
29491093 |
2018 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In addition, we identified a small subset of LS polyps with high mutational and neoantigen rates that were comparable to hypermutant tumors and displayed additional checkpoint (CTLA4 [cytotoxic T-lymphocyte-associated protein 4]) and neoantigens involved in DNA damage response (ATM and BRCA1 signaling).
|
29710228 |
2018 |
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To evaluate the role of constitutive epigenetic changes in normal body cells of BRCA1/BRCA2-mutation negative patients, we have developed a deep bisulfite sequencing assay targeting the promoter regions of 8 tumor suppressor (TS) genes (BRCA1, BRCA2, RAD51C, ATM, PTEN, TP53, MLH1, RB1) and the estrogene receptor gene (ESR1), which plays a role in tumor progression.
|
29659014 |
2018 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage.
|
29769307 |
2018 |
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Furthermore, variants of ATM gene had smaller tumor size, lower pathologic T stage at presentation, and more favorable surrogate molecular subtype compared to variants of other genes.
|
28986972 |
2018 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Conditioned medium mimicking the tumor microenvironment augments chemotherapeutic resistance via ataxia‑telangiectasia mutated and nuclear factor‑κB pathways in gastric cancer cells.
|
30106453 |
2018 |